BofA/Merrill Lynch Upgrades Orexigen Therapeutics (OREX) to Buy
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Price: $0.22 --0%
Rating Summary:
3 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 14
Rating Summary:
3 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 14
Join SI Premium – FREE
BofA/Merrill Lynch upgraded Orexigen Therapeutics (NASDAQ: OREX) from Neutral to Buy and raised their price target from $3.50 to $7.
For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $3.70 yesterday.
For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $3.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- S&P 500 eyes record as retail slump, Iran risk set up pivotal week
- BofA says US yen intervention may need stronger follow-up
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
